Metagenomi Therapeutics (MGX) Total Liabilities (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Total Liabilities of $59.2 million for Q1 2026, down 30.56% year-over-year from $85.2 million in Q1 2025, and down 5.34% quarter-over-quarter from $62.5 million in Q4 2025.
Metagenomi Therapeutics (MGX) Total Liabilities (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Total Liabilities for 4 consecutive years, with $59.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 30.56% year-over-year to $59.2 million; the TTM figure through Mar 2026 stood at $59.2 million (down 30.56% YoY), while the FY2025 annual figure was $62.5 million, down 30.35% from the prior year.
- Total Liabilities eased to $59.2 million in Q1 2026 per MGX's latest filing, from $62.5 million in the prior quarter.
- Across five years, Total Liabilities topped out at $149.7 million in Q4 2023 and bottomed at $59.2 million in Q1 2026.
- Historically, Total Liabilities has averaged $95.1 million across 4 years, with a median of $87.5 million in 2024.
- Annual changes were most pronounced in 2024 — Total Liabilities sank 40.04% — and 2025, when it plunged 30.35%.
- Metagenomi Therapeutics' Total Liabilities stood at $149.7 million in 2023, then tumbled by 40.04% to $89.7 million in 2024, then slumped by 30.35% to $62.5 million in 2025, then slipped by 5.34% to $59.2 million in 2026.
- Business Quant data shows MGX's Total Liabilities at $59.2 million in Q1 2026, $62.5 million in Q4 2025, and $69.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | 61.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 61.13 Mn |
| Mar 31, 2026 | 59.17 Mn |
| Dec 31, 2025 | 62.51 Mn |
| Sep 30, 2025 | 69.49 Mn |
| Jun 30, 2025 | 76.45 Mn |
| Mar 31, 2025 | 85.21 Mn |
| Dec 31, 2024 | 89.74 Mn |
| Sep 30, 2024 | 102.58 Mn |
| Jun 30, 2024 | 116.49 Mn |
| Mar 31, 2024 | 139.77 Mn |
| Dec 31, 2023 | 149.67 Mn |